OR WAIT null SECS
January 18, 2023
Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.
The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.
January 13, 2023
The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.
It is intended to identify the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning.
January 11, 2023
This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility.
The definitive agreement will give AstraZeneca global rights to CinCor’s portfolio of cardiorenal disease treatments.
Chiesi will acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in a deal worth up to $1.47 billion.
Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.
Sartorius and RoosterBio will work together to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.
January 10, 2023
The collaboration will see Moderna and CytomX work together to develop mRNA-based conditionally activated therapeutics.